Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IONS vs INCY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INCY Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 8–2 Matrix Metrics)

INCY Overall Winner 6-Pillar Tally: IONS 1 – 5 INCY Matrix Metrics: IONS 2 – 8 INCY

As of Nov 16, 2026, Incyte Genomics Inc (INCY) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas INCY carries 61.2/100 (BUY) at $119.86 (14.0x Forward P/E, 32.2% operating margin).

  • Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. INCY 61.2/100 BUY), INCY captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (32.2% vs. -58.8% operating margin) and revenue trajectory (+14.0% vs. +54.9% YoY).
  • Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile INCY trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 52.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IONS vs INCY
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07
INCY NASDAQ Head-to-Head Winner
Incyte Genomics Inc
Services-Commercial Physical & Biological Research
$119.86
-0.92% 1D
Market Cap $24.8B
TTM Revenue $6.01B
Forward P/E 14.0x
Beta / 30D Vol 0.30β · 35% Vol
Unified Composite Score
61.2 / 100 BUY
Tech 45.0 Fund 56.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.0 · SMA20: $118.59 · SMA50: $119.04

6-Pillar Scorecard Institutional Category Breakdown (IONS 1 – 5 INCY)

Columns: Metric · IONS · INCY
1. Valuation Multiples INCY
Forward P/E 90.9x 14.0x
Trailing P/E 90.9x 62.1x
PEG Ratio N/M 10.82x
EV / Revenue 6.2x 3.6x
2. Growth & Scale INCY
Revenue Growth (YoY) +54.9% +14.0%
Earnings Growth (YoY) -43.7% +37.7%
TTM Revenue (USD) $960M $6.01B
Market Cap $4.7B $24.8B
3. Profitability & Quality INCY
Gross Margin 3.0% 56.0%
Operating Margin -58.8% 32.2%
Net Profit Margin -56.9% 6.7%
Return on Equity (ROE) -108.0% 7.8%
4. Balance Sheet & Cash Flow INCY
Cash Generation (TTM) -$623M $680M
Cash Flow Margin -64.9% 11.3%
Net Cash / Leverage $1.33B Net Debt (4.14x D/E) $3.24B Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning INCY
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 59.9% (17th %ile) 36.5% (64th %ile)
Put/Call OI Skew 1.81x (Put-Skewed) 1.62x (Put-Skewed)
OBV Trend / Tech Phase DISTRIBUTION · Markdown DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity 61.8% of Rev ($593M) 23.8% of Rev ($1.43B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IONS (2) vs INCY (8)
Institutional Metric IONS INCY Criterion Row Edge
Market Capitalization
Scale
$4.7B $24.8B Larger Scale INCY
Trailing P/E Ratio
Valuation
90.9x 62.1x Lower Multiple INCY
Forward P/E Ratio
Valuation
90.9x 14.0x Lower Multiple INCY
Revenue Growth (YoY)
Growth
+54.9% +14.0% Higher Growth IONS
Operating Margin (TTM)
Profitability
-58.8% 32.2% Higher Margin INCY
Net Profit Margin
Profitability
-56.9% 6.7% Higher Margin INCY
Return on Equity (ROE)
Capital Efficiency
-108.0% 7.8% Higher ROE INCY
52-Week Range Position
Momentum
2% ($27–$87) 71% ($89–$133) Stronger Trend INCY
Beta / 30D Volatility
Risk Regime
0.18β · 86% Vol 0.30β · 35% Vol Lower Realized Risk INCY
Unified Institutional Score
Composite Signal
63.9 / 100 (BUY) 61.2 / 100 (BUY) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$960M $6.01B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.0% 56.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.2x EV/Rev 10.82x PEG · 3.6x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$623M ($1.33B Net Debt (4.14x D/E)) $680M ($3.24B Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon INCY +39.49 pp
IONS: -33.48% · INCY: +6.01%
3M Horizon INCY +49.17 pp
IONS: -52.09% · INCY: -2.92%
6M Horizon INCY +86.53 pp
IONS: -60.61% · INCY: +25.92%
1Y Horizon INCY +72.81 pp
IONS: -59.1% · INCY: +13.71%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IONS Revenue INCY Revenue IONS Op. Margin INCY Op. Margin Margin Leader
FY2018 $600M $1.88B -10.2% 6.9% INCY
FY2019 $1.12B $2.16B 32.6% 18.6% IONS
FY2020 $730M $2.67B -23.6% -9.9% INCY
FY2021 $810M $2.99B -3.7% 19.6% INCY
FY2022 $590M $3.39B -69.8% 17.1% INCY
FY2023 $790M $3.70B -44.9% 16.8% INCY
FY2024 $710M $4.24B -67.4% 1.4% INCY
FY2025 $940M $5.14B -40.4% 29.5% INCY

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INCY CONSOLIDATION
78d in phase · OBV DISTRIBUTION
Current IV 36.5%
IV Percentile 64th %ile
Put/Call OI Skew 1.62x (Put-Skewed)
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact INCY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published
INCY Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $24.8B market capitalization and 32.2% operating margin.
OpEx & R&D Reinvestment 23.8% of Rev ($1.43B)
90D Engineering Disclosures 0 Published

Investor FAQ IONS vs INCY Key Questions & Quantitative Answers

As of Nov 16, 2026, Incyte Genomics Inc (INCY) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas INCY carries 61.2/100 (BUY) at $119.86 (14.0x Forward P/E, 32.2% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. INCY 61.2/100 BUY), INCY captures the overall institutional head-to-head verdict (8–2 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (32.2% vs. -58.8% operating margin) and revenue trajectory (+14.0% vs. +54.9% YoY). Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile INCY trades in a Neutral technical trend (CONSOLIDATION options phase, RSI 52.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

INCY leads the Growth & Scale pillar: IONS posts +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin), compared with INCY at +14.0% YoY revenue growth and +37.7% YoY earnings growth on $6.01B TTM revenue (56.0% gross margin, 32.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IONS cumulative revenue shifted +56.7% while INCY shifted +173.4%. In operating R&D and SG&A reinvestment, IONS deploys 61.8% of Rev ($593M) (0 90-day corporate R&D disclosures) versus 23.8% of Rev ($1.43B) (0 disclosures) for INCY.

INCY screens cheaper on headline valuation multiples. IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin), whereas INCY trades at 14.0x Forward P/E, 62.1x Trailing P/E, 10.82x PEG, and 3.6x EV/Revenue (11.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONS (-108.0% ROE) versus INCY (7.8% ROE) capital efficiency.

In options market volatility and institutional positioning, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk). By comparison, INCY carries 36.5% implied volatility (64th %ile, Elevated (60th–80th %ile)), a 1.62x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.30β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.